Everest Medicines Eyes China Approval for LEROCHOL® PCSK9 Therapy
SHANGHAI, China, June 26, 2026 Everest Medicines announced a significant regulatory milestone after China’s National Medical Products Administration (NMPA)...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
SHANGHAI, China, June 26, 2026 Everest Medicines announced a significant regulatory milestone after China’s National Medical Products Administration (NMPA)...
INDIANAPOLIS, June 26, 2026 Eli Lilly and Company announced that the European Medicines Agency’s Committee for Medicinal Products for...
